Cost utility of itopride hydrochloride for the treatment of functional dyspepsia in Vietnam

No Thumbnail Available
File version
Author(s)
Kim, Hansoo
Byrnes, Joshua
Kim, Kyoo
Nguyen, Dinh Huy
Quach, Trong Duc
Tran, Thi Khanh Tuong
Nguyen, Thi Thu Cuc
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2023
Size
File type(s)
Location

Virtual

License
Abstract

Background: Functional dyspepsia (FD) is connected with abdominal pain and nausea, which leads to reduced quality of life, loss of productivity, and economic loss for patients. Itopride hydrochloride stimulates the gastrointestinal smooth muscles, thereby promoting gastric emptying, and has been shown to significantly improve symptoms in patients with FD without severe side effects. Itopride hydrochloride has been available in Vietnam for many years; however, the cost-effectiveness of the drug has not been established. The aim of this study is to estimate the cost-effectiveness of itopride hydrochloride for treatment of FD in Vietnam. Methods: A three-stage Markov model with the following health states: controlled FD, uncontrolled FD, and dead. FD was used to assess itopride over 10 years using 8-week cycles. From a broader Vietnamese societal perspective, input was retrieved from the literature and through local clinical experts. Output was reported as incremental cost-effectiveness ratio (ICER) per quality adjusted life years (QALY). A GDP/capita threshold (cost-effective: 1 × GDP = VND64.1M, cost-effective: 3 × GDP = VND192.2M) was used as the WHO and in Vietnam was used. One-way and probabilistic sensitivity analyses were performed. Results: Itopride hydrochloride resulted in additional 0.65 QALYs at an extra cost of VND29.1M. This resulted in an ICER of VND39.5M per QALY, which is lower than the threshold of VND192.2M. The one-sensitivity analyses showed that the ICER was sensitive to varying efficacy (ICER: VND24.8M to VND69.0M), cost of itopride (ICER: VND33.6M to VND45.4M), and the health utility values (ICER: VND35.9M to VND43.9M). More than 80% of the simulations in the probabilistic sensitivity analysis were cost-effective at the 1 × GDP (VND64.1M) threshold, and 91.3% were cost-effective at the 3 × GDP (VND192.2M) threshold. Conclusion: This study shows that itopride hydrochloride is the very cost-effective treatment for FD in Vietnam with the ICER (VND39.5M/QALY) being even lower than the 1 × GDP (VND64.1M) threshold.

Journal Title

Journal of Gastroenterology and Hepatology

Conference Title

Asian Pacific Digestive Week (APDW) 2022, 17–20 November 2022, Virtual

Book Title
Edition
Volume

38

Issue

S1

Thesis Type
Degree Program
School
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Gastroenterology and hepatology

Clinical sciences

Science & Technology

Life Sciences & Biomedicine

Gastroenterology & Hepatology

cost-effectiveness

economic loss

Persistent link to this record
Citation

Kim, H; Byrnes, J; Kim, K; Nguyen, DH; Quach, TD; Tran, TKT; Nguyen, TTC, Cost utility of itopride hydrochloride for the treatment of functional dyspepsia in Vietnam, Journal of Gastroenterology and Hepatology, 2023, 38 (S1), pp. 94-94